Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

109.85 +2.46 (+2.29%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Enrollment completed six months early; $1.5B cash runway into 2029.

Via The Motley Fool

Topics Earnings

Kymera Therapeutics Q2 Earnings Call Highlights ↗

August 05, 2026

Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by...

Via MarketBeat

Topics Earnings

Kymera's CEO Sold $6 Million in Stock After a 170% Run ↗

July 12, 2026

This execution under a pre-scheduled Rule 10b5-1 plan follows 172% one-year stock surge.

Via The Motley Fool

Topics Regulatory Compliance

Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat ↗

April 30, 2026

Via Chartmill

Kymera Therapeutics Inc (NASDAQ:KYMR) Stock Falls 6.6% After Q4 2025 Earnings Miss and Extended Clinical Timelines ↗

February 26, 2026

Via Chartmill

Topics Earnings

Why Kymera Therapeutics Stock Popped This Week ↗

June 26, 2026

It's getting quite the head start on an important clinical trial.

Via The Motley Fool

These stocks are gapping in today's session ↗

June 25, 2026

Via Chartmill

Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data ↗

May 26, 2026

Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while...

Via MarketBeat

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗

May 17, 2026

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

Via The Motley Fool

Topics Regulatory Compliance

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗

May 17, 2026

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Via The Motley Fool

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.

Via The Motley Fool

Topics Initial Public Offering

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.

Via The Motley Fool

Topics Regulatory Compliance

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗

March 09, 2026

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗

March 06, 2026

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Kymera (KYMR) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet ↗

February 23, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.

Via The Motley Fool

Topics Regulatory Compliance

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks ↗

January 01, 2026

Via MarketBeat

Streaming Wars Go Hostile Just as Wall Street Braces for the Fed ↗

December 09, 2025

Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with...

Via Chartmill

Topics Economy

Let's take a look at the stocks that are in motion in today's session. ↗

December 08, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

What's going on in today's session ↗

December 08, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 08, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.